InvestorsHub Logo
icon url

masterlongevity

02/15/12 2:25 PM

#137091 RE: DewDiligence #137074

4Q11 US Copaxone sales were ~$740M, compared to tysabri US Q4 of $170M
icon url

jq1234

02/20/12 7:19 PM

#137435 RE: DewDiligence #137074

TEVA: According to FDA News, Teva decided not to file Laquinimod NDA for relapsing remitting multiple sclerosis (RRMS) after discussion with FDA.

No surprise there.